The results showed that targeting MYC activation by CRISPR/dCasRx-SINEB2 promotes tumor development and metastasis (Supplementary Figure S11), but targeting EGFP activation has no significant impact on cell mobility (Supplementary Figure S12). This evidence concerns the gene MYC and neoplasm.